Epicrispr secures $90M Series C to advance epigenetic therapy for rare muscle disease
Epicrispr Biotechnologies announced a $90 million Series C financing round, led by Octagon Capital and Janus Henderson Investors, with participation from Sanofi Ventures and other investors.
The capital will be used to move forward its pipeline of epigenetic medicines, centered on an early-phase candidate for facioscapulohumeral muscular dystrophy (FSHD).
In a Phase 1/2 trial of the FSHD drug EPI-321, three patients showed modest gains in lean muscle mass-between 0.5 and 1.3 pounds-six months after a single intravenous infusion, providing preliminary support for the approach of suppressing DUX4 expression.
The readout, while early, bolsters the company's hypothesis that epigenetic editing can mitigate the toxic DUX4 protein and improve outcomes for patients with this rare muscle-degeneration disease.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Epicrispr raises $90M to rewrite treatment of rare muscle disease”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that